Targeted medicines, cell-based therapies, specialist technologies and clinical research may raise new questions about your care. HSMC connects those questions with relevant specialist teams in China, starting with your diagnosis, treatment history and goals.
A free introductory HSMC meeting helps clarify your request. Specialist medical review is a separate paid service.
You may be reviewing a new treatment suggestion, seeking options after a previous treatment, or asking about a technology you have heard about. These are directions for specialist discussion; a named therapy is not an offer of treatment or an open trial place.
Bring your pathology, molecular or biomarker results, previous medicines and treatment response. Ask whether the specialist identifies further approved options or a relevant investigational medicine.
Cancer Care ↗Ask the relevant hematology or oncology team about the exact cell therapy, intended indication and clinical requirements. Approval for one disease does not establish suitability or access for another.
Cancer Care ↗Shanghai examples include 360° image-guided proton therapy at Ruijin Hospital and single-port robotic thoracic surgery. Investigational directions include transcatheter mitral valve replacement at Zhongshan Hospital and focused-ultrasound-assisted drug delivery for glioblastoma at Huashan Hospital. Ask which approach fits your diagnosis, whether it is clinical care or research, and what further assessment is required.
These are examples from dated hospital, research-institution or device-developer reports, checked on 2 November 2026. Current availability, relevant indication, study recruitment and international-patient acceptance must be confirmed with the responsible team.
For a defined neurological or functional goal, ask whether a relevant team can consider your case. Confirm the device, intended use and clinical or research status of the specific program.
Neurology & Neurosurgery ↗The specialist considers whether a medicine, procedure or device is appropriate for your condition. The hospital confirms its status in China, relevant indication, local availability and clinical requirements.
A trial studies a medical question. Its team determines recruitment, eligibility, screening and enrollment. A registry entry or preliminary record review does not confirm an available place.
For CAR-T, BCI and other emerging technologies, the exact product, indication and program status matter. HSMC helps coordinate the inquiry; the medical or research team determines clinical recommendations and eligibility.
We clarify your diagnosis, previous treatment, current recommendation and the question you want answered. Records are shared only after authorization and recipients are agreed.
Start with the agreed Second Opinion service. You may specify an institution or ask HSMC to recommend a relevant team. A second-team review can be discussed where useful and agreed.
If an option is identified and further inquiry is agreed, we coordinate questions about the named institution, clinical or trial status, recruitment, eligibility and additional assessments. The receiving team confirms what it can consider.
Before travel, agree the visit or screening plan, expected time commitment, costs and care responsibilities. Trial enrollment may still depend on on-site screening. If no pathway is available, discuss the specialist’s alternative recommendations.
Confirm the accepting institution, required assessments, treatment or study schedule, repeat visits and anticipated time in China. A short visit may not fit the program. Do not treat an initial inquiry as confirmed admission.
Ask which medicines, research tests and routine care costs are covered by the study, sponsor, hospital or patient. Agree HSMC’s review and coordination scope separately. Research participation does not automatically mean all care or travel is free.
Identify the Shanghai contact and your local treating clinician. Clarify monitoring, urgent-care arrangements, reporting of side effects and required return visits. Remote communication does not replace the study’s required follow-up.
Confirm language support and how you will understand the study and consent documents. Your clinical team explains medical choices; the research team conducts study consent. HSMC supports the agreed communication and practical arrangements.
Tell us what you have first. We confirm patient authorization, intended recipients and the submission route before you send medical documents. The reviewing team decides whether further tests or samples are needed.
Not necessarily. Trials have different purposes and eligibility criteria, and some consider people earlier in their treatment. The relevant specialist and study team assess timing against your clinical situation and the protocol.
No. Availability, medical suitability, study recruitment and enrollment require confirmation by the responsible institution. An inquiry, paid review or coordination agreement does not secure access or guarantee a treatment outcome.
Yes, a specialist review can be coordinated using the agreed records. The reviewing team determines what can be addressed remotely. Further examination, testing or on-site screening may be required.
Acceptance is confirmed study by study. The research site must consider the protocol, documentation, communication, follow-up and other applicable requirements. International status alone does not establish eligibility.
The specialist may discuss approved treatment options, further assessment or continuing care with your existing team. A useful review can clarify why a suggested option is unsuitable or what information is missing; it does not promise a trial match.
Confirm the team, your questions and the review scope before the service begins. Ask about relevant treatment options and whether further clinical or research inquiries are appropriate.
The review fee is separate from hospital charges and any later treatment or trial coordination. Full service terms and fees are listed on Services & Fees.
Share the diagnosis, treatment already received and the specific option or question you want a specialist to consider.
General educational resources. These links do not identify an HSMC program, establish Chinese approval or confirm current trial recruitment.